About Dr Jamie Triccas
To understand how pathogenic bacteria interact with the host immune system, in order to develop better vaccines and antibiotics
Dr Triccas is a Senior Research Fellow at the University of Sydney whose laboratory studies how lung pathogens interact with the immune system, and how this information can be used to develop new strategies to treat infection.
Dr Jamie Triccas is head of the Microbial Immunity and Pathogenesis Group located in the Discipline of Infectious Diseases and Immunology at the University of Sydney. He received both his BSc (Hons) and PhD from the University of Sydney. He was previously a Cantarini Research Fellow at the Pasteur Institute in Paris (1997-1999) and a Senior Research Fellow at the Centenary Institute in Sydney (1999-2004). In 2006 Dr Triccas was awarded a NHMRC Biomedical Career Development Award to further his research into the host response to bacterial pathogens and vaccine development. The research program of Dr Triccas is focused on determining how virulent micro-organisms promote disease, and developing novel strategies to prevent infection. A particular emphasis of his research is determining which components of the immune response are targeted by pathogenic mycobacteria during infection, and using this information to aid the rational development of more effective anti-tuberculosis vaccines. One of the vaccines developed by his group is currently under evaluation as part of the NIH Tuberculosis Vaccine Testing Contract at the University of Colorado and other vaccines developed by Dr Triccas are being prepared for pre-clinical testing. The group is also defining in detail the T cell immune response induced by infection with virulent lung pathogens, by the use of T cell receptor transgenic models developed in the laboratory. It is hoped that such studies will aid the rational design of new vaccines engineered to stimulate immune function. More recently, Dr Triccas has commenced projects aimed at discovering new compounds that could be used as treatments to control infection with the lung pathogens Mycobacterium tuberculosis and Pseudomonas aeruginosa (a major opportunistic infection in patients with cystic fibrosis).